moxifloxacin and cem 101
moxifloxacin has been researched along with cem 101 in 5 studies
Compound Research Comparison
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (cem 101) | Trials (cem 101) | Recent Studies (post-2010) (cem 101) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 84 | 13 | 75 |
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fernandes, P; Jensen, JS; Unemo, M | 1 |
| Muccioli, GG; Tulkens, PM; Van Bambeke, F; Vandevelde, NM | 1 |
| Antonovsky, Y; Barrera, CM; Clark, K; Das, AF; Doreski, PA; Fernandes, P; Flores-Figueroa, J; Horwith, G; Jamieson, B; Karimjee, N; Keedy, K; Metev, H; Mitha, I; Molina, JM; Mykietiuk, A; Nitu, MF; Oldach, D; Rewerska, B; Rowe, BH; Scott, D; Sheets, A; Tanaseanu, CM; Van Rensburg, DJ | 1 |
| Das, AF; Fernandes, P; File, TM; Gonong, JRV; Jamieson, BD; Keedy, K; Oldach, D; Rewerska, B; Sheets, A; Taylor, D; Vucinic-Mihailovic, V | 1 |
| Darpo, B; Fernandes, P; Jamieson, BD; Keedy, K; Oldach, D; Sager, PT; Zhou, M | 1 |
Trials
3 trial(s) available for moxifloxacin and cem 101
| Article | Year |
|---|---|
Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Europe; Female; Fluoroquinolones; Humans; Latin America; Macrolides; Male; Middle Aged; Moxifloxacin; North America; Pneumonia, Bacterial; South Africa; Triazoles; Young Adult | 2016 |
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Comorbidity; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Macrolides; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Treatment Outcome; Triazoles | 2016 |
Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects.
Topics: Arrhythmias, Cardiac; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Humans; Macrolides; Male; Moxifloxacin; Placebos; Triazoles | 2017 |
Other Studies
2 other study(ies) available for moxifloxacin and cem 101
| Article | Year |
|---|---|
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.
Topics: Anti-Bacterial Agents; Azithromycin; DNA, Bacterial; DNA, Ribosomal; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycoplasma genitalium; Mycoplasma Infections; Neisseria gonorrhoeae; Triazoles | 2014 |
Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms.
Topics: Aged; Aged, 80 and over; Albuterol; Anti-Bacterial Agents; Biofilms; Bronchodilator Agents; Chromatography, High Pressure Liquid; Drug Interactions; Female; Fluoroquinolones; Humans; Ipratropium; Macrolides; Male; Mass Spectrometry; Microbial Viability; Middle Aged; Models, Theoretical; Moxifloxacin; N-Acetylneuraminic Acid; Pneumococcal Infections; Streptococcus pneumoniae; Triazoles | 2015 |